Chinese Biotech Firm Metis TechBio Signs Drug-Development Deal Worth Up to US$1.1 Billion

On 21 October, City News Service reported that China’s Metis TechBio had entered into an agreement with Eli Lilly valued at up to US$1.1 billion to research and develop tissue-specific drug-delivery technologies. The maximum headline value is contingent on the agreement’s terms and is not necessarily an upfront payment; pharmaceutical companies, research institutions and healthcare technology providers can explore clinical-data analysis and research-computing requirements, while HPC can provide suitable data-processing support with quotations based on confirmed project needs.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.